40 likes | 116 Views
LABORATORY MONITORING OF HIV INFECTION. SESSION WEPDB01 13:00-14:00 HRS Wednesday, July 25, 2012. Participants. Chair Robert W. Coombs, MD, PhD, FRCPC University of Washington, Seattle, WA POSTER PRESENTORS WEPDB0101: Howard Gale , MD, MT (ASCP) VA Medical Center, Washington, DC
E N D
LABORATORY MONITORING OF HIV INFECTION SESSION WEPDB01 13:00-14:00 HRS Wednesday, July 25, 2012 SESSION WEPDB01: Laboratory Monitoring of HIV Infection
Participants • Chair • Robert W. Coombs, MD, PhD, FRCPC • University of Washington, Seattle, WA • POSTER PRESENTORS • WEPDB0101: Howard Gale, MD, MT (ASCP) • VA Medical Center, Washington, DC • WEPDB0102: Charlotte Charpentier, PharmD, PhD • Laboratoire de Virologie; HôpitalBichat-Claude Bernard; Paris, France • WEPDB0103: Kenneth Ouma, PhD • KEMRI-CDC, Kisumu, Kenya • WEPDB0104: Dana Raugi, MPH • University of Washington, Seattle, WA SESSION WEPDB01: Laboratory Monitoring of HIV Infection
RULES • 5 minute presentation; 2 minutes for clarification • 30 minutes for questions & general discussion between the panelists and audience • We will focus on four questions of relevance to the resource-limited setting SESSION WEPDB01: Laboratory Monitoring of HIV Infection
Questions • LABORATORY MONITORING OF HIV INFECTION: • What is the ideal testing frequency for HIV RNA and CD4 monitoring? • VIRAL SUPPRESSION: • What level of HIV-1 RNA defines “virological” failure? • DRIED BLOOD SPOTS: • Simple/rapid specimen collection and testing – what is required to validate DBS for HIV RNA/DNA? • DUAL HIV-1/-2 INFECTION: • Do we need better dual diagnostic tests for HIV-1/-2? SESSION WEPDB01: Laboratory Monitoring of HIV Infection